{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:29:04Z","timestamp":1760711344020},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jdcr.2024.03.028","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T16:43:33Z","timestamp":1715013813000},"page":"129-131","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Abrupt progression from patch- to tumor-stage mycosis fungoides following pembrolizumab treatment"],"prefix":"10.1016","volume":"49","author":[{"given":"Gyeong Hoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Min","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong Hyun","family":"Won","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Eun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.jdcr.2024.03.028_bib1","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jdcr.2024.03.028_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V128.22.181.181","article-title":"Pembrolizumab for treatment of relapsed\/refractory mycosis fungoides and sezary syndrome: clinical efficacy in a citn multicenter phase 2 study","volume":"128","author":"Khodadoust","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jdcr.2024.03.028_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000104","article-title":"T-cell lymphoma secondary to checkpoint inhibitor therapy","volume":"8","author":"Anand","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.jdcr.2024.03.028_bib4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jdcr.2018.01.016","article-title":"Cutaneous CD56(+) T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma","volume":"4","author":"Zheng","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"8","key":"10.1016\/j.jdcr.2024.03.028_bib5","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jdcr.2024.03.028_bib6","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jdcr.2020.09.020","article-title":"Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment","volume":"6","author":"Duke","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.jdcr.2024.03.028_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jdcr.2019.11.005","article-title":"Pembrolizumab-associated tumor development in a patient with Sezary syndrome","volume":"6","author":"Malachowski","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.jdcr.2024.03.028_bib8","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.164793","article-title":"Hyperprogression of cutaneous T cell lymphoma after anti\u2013PD-1 treatment","volume":"8","author":"Gao","year":"2023","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.jdcr.2024.03.028_bib9","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","article-title":"Hyperprogressive disease in patients with advanced non\u2013small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy","volume":"4","author":"Ferrara","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.jdcr.2024.03.028_bib10","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/bjd.12909","article-title":"Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: where are we now?","volume":"170","author":"Scarisbrick","year":"2014","journal-title":"Br J Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624001668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624001668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T15:49:47Z","timestamp":1721058587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512624001668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":10,"alternative-id":["S2352512624001668"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.03.028","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abrupt progression from patch- to tumor-stage mycosis fungoides following pembrolizumab treatment","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}